Hepatoblastoma is a type of liver tumor that occurs in infants and children.
Research investigates the impact of Caesarean section birth on obesity at 3 years of age in Japanese children. The study found that Caesarean birth modestly increases the risk of obesity at 3 years of age in Japanese children.
Although rare compared to adult liver cancers, hepatoblastoma is the most common pediatric liver malignancy, and its incidence is increasing.
Scientific studies suggest that children with birth defects are at increased risk of cancer. However, it has not been assessed whether the type of cancer, the age at which they are diagnosed or the extent of cancer spread at the time of diagnosis, is different for children with birth defects compared to children without birth defects.
Hepatoblastoma is a rare form of liver cancer affecting just a few individuals per million. However, it is the leading cause of liver cancer in infants and young children, with most patients diagnosed before their third birthday.
The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Fellowship Award, committing nearly $1 million to help address a critical shortage of funding for pediatric cancer research.
Childhood cancer is a rare occurrence in the overall population but may be somewhat more frequent in children born with birth defects.
Scientists investigating have discovered a notable link between childhood cancer development and IVF.
A protein in the cell nucleus already targeted therapeutically for several types of cancer has now been linked to an aggressive form of pediatric liver cancer called hepatoblastoma (HBL), according to a study published in the Nature journal Communications Biology.
Hepatoblastoma is a rare pediatric liver cancer, usually diagnosed in the first three years of life. Histological methods are used to distinguish between the different subtypes of hepatoblastoma.
Investigators at Children's Hospital Los Angeles have succeeded in better defining a rare pediatric malignant liver disease -- a necessary step in achieving an optimum treatment.
Treatments for childhood cancers have improved to the point that 5-year survival rates are over 80 percent. However, one group has failed to benefit from these improvements, namely children who die so soon after diagnosis that they are not able to receive treatment, or who receive treatment so late in the course of their disease that it is destined to fail.
Investigators from Children's Hospital Los Angeles and 37 other Children's Oncology Group hospitals in the U.S. and Canada have determined that sodium thiosulfate prevents cisplatin-induced hearing loss in children and adolescents with cancer.
Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.
Fennec Pharmaceuticals, Inc., announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)."
In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the "genomic landscape" of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.
Newly-identified cancer cell fingerprints in the blood could one day help doctors diagnose a range of children's cancers faster and more accurately, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference next week.
A study of pediatric patients with hepatoblastoma led by researchers at Children's Hospital Los Angeles (CHLA) suggests an opportunity to reduce chemotherapy in up to 65 percent of patients, which could lead to a decrease in the incidence of adverse effects.
Researchers at the Children-s Medical Center Research Institute at UT Southwestern have identified a gene that contributes to the development of several childhood cancers, in a study conducted with mice designed to model the cancers.
A multistate study led by researchers at the University of Utah has revealed that the risk for childhood cancer is moderately increased among children and young adolescents with certain types of major birth defects.
Scientists have identified a genetic signature that is remarkably effective at predicting the prognosis of an aggressive liver cancer in children.